Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Neutrophil Fc gamma RI as target for immunotherapy of invasive candidiasis.

van Spriel AB, van den Herik-Oudijk IE, van de Winkel JG.

J Immunol. 2001 Jun 15;166(12):7019-22.

2.

Effective phagocytosis and killing of Candida albicans via targeting FcgammaRI (CD64) or FcalphaRI (CD89) on neutrophils.

van Spriel AB, van den Herik-Oudijk IE, van Sorge NM, Vilé HA, van Strijp JA, van de Winkel JG.

J Infect Dis. 1999 Mar;179(3):661-9.

PMID:
9952373
3.

Generation of HER-2/neu-specific cytotoxic neutrophils in vivo: efficient arming of neutrophils by combined administration of granulocyte colony-stimulating factor and Fcgamma receptor I bispecific antibodies.

Heijnen IA, Rijks LJ, Schiel A, Stockmeyer B, van Ojik HH, Dechant M, Valerius T, Keler T, Tutt AL, Glennie MJ, van Royen EA, Capel PJ, van de Winkel JG.

J Immunol. 1997 Dec 1;159(11):5629-39.

PMID:
9548506
4.

Lysis of murine B lymphoma cells by transgenic phagocytes via a human Fc gamma RI x murine MHC class II bispecific antibody.

Heijnen IA, Glennie MJ, van de Winkel JG.

Cancer Immunol Immunother. 1997 Nov-Dec;45(3-4):166-70.

PMID:
9435865
5.

Therapeutic efficacy of FcgammaRI/CD64-directed bispecific antibodies in B-cell lymphoma.

Honeychurch J, Tutt AL, Valerius T, Heijnen IA, Van De Winkel JG, Glennie MJ.

Blood. 2000 Nov 15;96(10):3544-52.

6.

A single injection of polyethylene-glycol granulocyte colony-stimulating factor strongly prolongs survival of mice with systemic candidiasis.

van Spriel AB, van den Herik-Oudijk IE, van de Winkel JG.

Cytokine. 2000 Jun;12(6):666-70.

PMID:
10843742
7.

Subcutaneous administration of interleukin-2 triggers Fcgamma receptor I expression on human peripheral blood neutrophils in solid and hematologic malignancies.

Sconocchia G, Cococcetta NY, Campagnano L, Amadori S, Iorio B, Boffo V, Ferdinandi V, Del Principe I, Adorno D, Casciani CU.

J Immunother. 2001 Jul-Aug;24(4):374-83.

PMID:
11565839
8.

Mice lacking both G-CSF and IL-6 are more susceptible to Candida albicans infection: critical role of neutrophils in defense against Candida albicans.

Basu S, Quilici C, Zhang HH, Grail D, Dunn AR.

Growth Factors. 2008 Feb;26(1):23-34. doi: 10.1080/08977190801987513.

PMID:
18365876
9.

Effective targeting of pathogens to neutrophils via chimeric surfactant protein D/anti-CD89 protein.

Tacken PJ, Hartshorn KL, White MR, van Kooten C, van de Winkel JG, Reid KB, Batenburg JJ.

J Immunol. 2004 Apr 15;172(8):4934-40.

10.

G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER-2/neu (MDX-210).

Repp R, Valerius T, Wieland G, Becker W, Steininger H, Deo Y, Helm G, Gramatzki M, Van de Winkel JG, Lang N, et al.

J Hematother. 1995 Oct;4(5):415-21. Review.

PMID:
8581378
11.

Receptor modulation by Fc gamma RI-specific fusion proteins is dependent on receptor number and modified by IgG.

Guyre CA, Keler T, Swink SL, Vitale LA, Graziano RF, Fanger MW.

J Immunol. 2001 Dec 1;167(11):6303-11.

12.

Unique monoclonal antibodies define expression of Fc gamma RI on macrophages and mast cell lines and demonstrate heterogeneity among subcutaneous and other dendritic cells.

Tan PS, Gavin AL, Barnes N, Sears DW, Vremec D, Shortman K, Amigorena S, Mottram PL, Hogarth PM.

J Immunol. 2003 Mar 1;170(5):2549-56.

13.

Enhancement of polymorphonuclear cell-mediated tumor cell killing on simultaneous engagement of fcgammaRI (CD64) and fcalphaRI (CD89).

van Egmond M, van Spriel AB, Vermeulen H, Huls G, van Garderen E, van de Winkel JG.

Cancer Res. 2001 May 15;61(10):4055-60.

14.

Targeting weak antigens to CD64 elicits potent humoral responses in human CD64 transgenic mice.

Keler T, Guyre PM, Vitale LA, Sundarapandiyan K, van De Winkel JG, Deo YM, Graziano RF.

J Immunol. 2000 Dec 15;165(12):6738-42.

15.

A phagocytic cell line markedly improves survival of infected neutropenic mice.

Spellberg BJ, Collins M, French SW, Edwards JE Jr, Fu Y, Ibrahim AS.

J Leukoc Biol. 2005 Aug;78(2):338-44. Epub 2005 Apr 27.

PMID:
15857941
16.

Granulocyte-colony stimulating factor enhances chimeric antibody Nd2 dependent cytotoxicity against pancreatic cancer mediated by polymorphonuclear neutrophils.

Tamamori Y, Sawada T, Nishihara T, Yamashita Y, Ohira M, Ho JJ, Kim YS, Hirakawa-Y S Chung K.

Int J Oncol. 2002 Sep;21(3):649-54.

PMID:
12168113
17.

CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations.

van Ojik HH, Bevaart L, Dahle CE, Bakker A, Jansen MJ, van Vugt MJ, van de Winkel JG, Weiner GJ.

Cancer Res. 2003 Sep 1;63(17):5595-600.

18.

Macrophage-colony stimulating factor is required for the production of neutrophil-promoting activity by mouse embryo fibroblasts deficient in G-CSF and GM-CSF.

Zhang HH, Basu S, Wu F, Begley CG, Saris CJ, Dunn AR, Burgess AW, Walker F.

J Leukoc Biol. 2007 Oct;82(4):915-25. Epub 2007 Jul 25.

PMID:
17652450
19.

Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcgammaRI x anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer.

Repp R, van Ojik HH, Valerius T, Groenewegen G, Wieland G, Oetzel C, Stockmeyer B, Becker W, Eisenhut M, Steininger H, Deo YM, Blijham GH, Kalden JR, van de Winkel JG, Gramatzki M.

Br J Cancer. 2003 Dec 15;89(12):2234-43.

20.

Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice.

Huang W, Na L, Fidel PL, Schwarzenberger P.

J Infect Dis. 2004 Aug 1;190(3):624-31. Epub 2004 Jun 22.

PMID:
15243941

Supplemental Content

Support Center